Search

Copenhagen-based SNIPR Biome, a CARB-X portfolio company, has developed SNIPR001, a cocktail of CRISPR-armed phages designed to target E. coli. A recent release by Robin Berghaus of CARB-X highlights the potential of SNIPR001 to prevent blo

BiomX analyzed a set of colorectal cancer tumour samples from patients, and found that 80% contained Fusobacterium nucleatum, which BiomX has been engineering phages to target. BiomX's phages are designed to deliver payloads that make tumou

Aurélie Fluckiger (Gustave Roussy Cancer Campus, France) and colleagues published a new paper in Science showing cross-reactivity between tumor antigens and the tape measure protein encoded by an Enterococcus hirae prophage. Administering e